Table 3.
LAM10_CAM distribution of drug resistance, gender, and age of the studied subjects
| LAM10_CAM (%) | Other clades (%) | Total | p-value | |
|---|---|---|---|---|
| STR | 0.287 | |||
| S | 86 (67.2) | 55 (74.3) | 141 | |
| R | 42 (32.8) | 19 (25.7) | 61 | |
| INH | 0.841 | |||
| S | 97 (75.8) | 57 (77) | 154 | |
| R | 31 (24.2) | 17 (23) | 48 | |
| RIF | 0.841 | |||
| S | 97 (75.8) | 57 (77) | 154 | |
| R | 31 (24.2) | 17 (23) | 48 | |
| ETH | 0.281 | |||
| S | 121 (94.5) | 67 (90.5) | 188 | |
| R | 7 (5.5) | 7 (9.5) | 14 | |
| Gender | 0.038 | |||
| Male | 91 (71.1) | 42 (56.8) | 133 | |
| Female | 37 (28.9) | 32 (43.2) | 69 | |
| Age | 0.015 | |||
| 15–24 | 14 (10.9) | 14 (18.9) | 28 | |
| 25–34 | 46 (35.9) | 39 (52.7) | 85 | |
| 35–44 | 40 (31.3) | 13 (17.6) | 53 | |
| 45–54 | 17 (13.3) | 6 (8.1) | 23 | |
| ≥55 | 11 (8.6) | 2 (2.7) | 13 | |
| Total | 128 | 74 | 202 | |
STR, streptomycin; INH, isoniazid; RIF, rifampicin; ETH, ethambutol; S, sensitive; R, resistant.